Use of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography to Monitor Disease Activity in Patients With Giant Cell Arteritis on Tocilizumab.

ABSTRACT:

Objective

The objective of this study was to assess the value of ¹⁸F-fluorodeoxyglucose (FDG)- positron emission tomography (PET) scans to monitor disease activity in patients with giant cell arteritis (GCA) on tocilizumab.

Methods

Patients with GCA were recruited into a prospective cohort in which they underwent clinical, laboratory, and imaging assessments, including FDG-PET. FDG-PET scans were interpreted as active or inactive based on global impression by two independent readers. The PET Vascular Activity Score (PETVAS) was calculated to quantify arterial FDG uptake (scale 0-27). Vascular FDG-PET findings were described in patients with GCA on tocilizumab for at least six months. For patients in established clinical remission, FDG-PET findings were compared be

SUBMITTER: Quinn KA 

PROVIDER: S-EPMC11795057 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature